Cell and gene therapy

#Cell and gene therapy #Drug development #Drug discovery #Webinar

CGT Webinar: Innovating for the future

On February 17 at 8am PST / 11am EST / 4pm GMT / 5pm CET, join DDW to enjoy this free webinar, Cell and gene therapy: sustaining growth and maximising opportunities. Cell and gene therapies (CGT) are transforming the way diseases are treated. As research progresses it is hoped… Read More

#News

#AAV #Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #RNA

Keep up to date: DDW Highlights 30 January 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Cell and gene therapies have been making the news this week, as… Read More

#News

#Cell and gene therapy #Drug development #Drug discovery #Webinar

Webinar: Transforming disease treatment with CGT

Register to attend Cell and gene therapy: sustaining growth and maximising opportunities, a free-to-attend DDW webinar, supported by Benchling and BPS Bioscience, on February 17, 2023 at 8am PST / 11am EST / 4pm GMT / 5pm CET.  Cell and gene therapies (CGT) are transforming the way diseases… Read More

#News

#AAV #Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #RNA

This week in drug discovery (23-27 January)

News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer. Cell and gene therapies have been making the news this week, as we launch our very own guide to global… Read More

#News

Gene therapy
#Cell and gene therapy #Gene therapy #Investment #Muscular dystrophy #Seed funding #Start-ups

$5 million raised towards gene therapies for muscular diseases

Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne.  The capital will go towards developing Myosana’s gene therapy platform for neuromuscular and cardiac disease, with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.  “Built on decades… Read More

#Business & Investment #News #Start-up Zone

#AI / data analytics / healthtech / informatics #Cell and gene therapy #Magazine #Oncology #SLAS2023

DDW Winter issue out now

The Winter 2022/2023 issue of Drug Discovery World Magazine is out now. Featuring a Therapeutic Spotlight on Oncology, the magazine is available to download free here and read for free on the DDW App. You can also request to receive a copy of the printed magazine here. Read More

#Editor's Choice #News

#Cell and gene therapy #Drug development #Drug discovery #Webinar

Learn about sustaining growth and maximising opportunities in CGT

Cell and gene therapies (CGT) are transforming the way diseases are treated. As research progresses it is hoped that cell and gene therapies will offer innovation for the future. Join this free webinar, hosted by DDW and supported by BPS Bioscience and Benchling, to learn… Read More

#News

#Cell and gene therapy #Drug development #Drug discovery

Cell and gene therapy: sustaining growth and maximising opportunities

Cell and gene therapies are transforming the way diseases are treated. As research progresses it is hoped that cell and gene therapies will offer innovation for the future. In this on-demand webinar you will hear from CBO/CDO of Adthera Bio, Stuart Curbishley, Chief Executive Officer of Cell & Gene Therapy… Read More

Webinar date:
Sponsored by Benchling and BPS Bioscience
#Webinars

EMA
#AAV #Cell and gene therapy #European Medicines Agency #Forge Biologic #Gene therapy #Priority Review

EMA prioritises AAV gene therapy for Krabbe disease

The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge Biologic’s adeno-associated virus (AAV) drug candidate for treating patients with Krabbe disease.  PRIME is a regulatory designation by the EMA that provides early and proactive support to developers of promising medicines, to advance and speed up… Read More

#News #Regulatory

Child with cystic fibrosis on ventilator
#Cell and gene therapy #Cystic fibrosis #European Commission #Gene therapy #Krystal Biotech #Orphan drugs

Gene therapy for cystic fibrosis receives EC orphan drug designation

The European Commission has granted orphan designation for Krystal Biotech’s KB407 for the treatment of cystic fibrosis (CF).  KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of cystic fibrosis by delivering two copies of the CFTR gene directly to the airway epithelial cells when delivered… Read More

#News #Regulatory

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Guide

Exclusive insight into cell and gene therapy

Download this exclusive cell and gene therapy guide to learn about: The successes of cell and gene therapies plus the biggest questions facing the sector Expert views on the challenges and opportunities for cell and gene therapies in 2023 Understanding future road maps of cell and gene therapies Why there… Read More

#DDW eBooks

#Cell and gene therapy #Drug development #Drug discovery #Guide

Latest DDW Guide: Exclusive insight into cell & gene therapy

DDW has published the first of its new Guide Series, Where is the global innovation and the opportunity in cell and gene therapy? It is sponsored by Astrea BioSeparations and Benchling.  In this free, exclusive guide, you will learn more about:  The successes… Read More

#News

#Advanced Therapies #Cell and gene therapy

Reflections from Advanced Therapies Week 2023 

Over the three days of Advanced Therapies Week (ATW) 2023 in Miami, Florida, US, from 18 to 20 January, DDW’s Megan Thomas heard from attendees about what they were most looking forward to learning from the event, as well as why they think the potential of cell and gene therapies… Read More

#Exclusive Content #Opinion

#Biopharma #Cell and gene therapy #Drug discovery #Stem cells

The use of base editing in stem cell-based therapies

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies.   Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential… Read More

#Exclusive Content

#Cell and gene therapy #Immunology / Virology & Vaccines #mRNA #pDNA

Early phase support for plasmid DNA supply to secure future manufacturing

This paid-for advertorial by Catalent appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 One significant challenge in the manufacturing of cell and gene therapies is the production of high-quality plasmid DNA (pDNA). pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and… Read More

#Exclusive Content

#AAV #Cell and gene therapy #Drug delivery #Gene delivery #Gene therapy #mRNA #Nanomedicine / nanotechnology #Ophthalmology

Lipid nanoparticles and mRNA used to treat hereditary blindness

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition.  Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. … Read More

#News #Trending News